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One Sentence Summary: HCV entry inhibition improves end-of-treatment antiviral response in 
human-liver chimeric mice by restricting on-therapy breakthrough of HCV mutants that are 
resistant to direct-acting antivirals. 
Keywords: HCV, entry inhibition, resistance, mouse model, therapy 
Word count: 3332 
Abbreviations: HCV, Hepatitis C virus; DAA, Direct-Acting Antiviral; RAV, resistance-
associated variants; PEG-IFN, pegylated interferon; RBV, ribavirin; PI, protease inhibitor; SR-
BI, Scavenger Receptor class B type I; mAb, monoclonal antibody; SVR, sustained virologic 
response; LOQ, limit of quantification; EOT, end-of-treatment; uPA, urokinase-type 
plasminogen activator; SCID, severe combined immune deficient; gt, genotype 
 
Abstract: 
Objective: Direct-Acting Antivirals (DAAs) inhibit HCV infection by targeting viral proteins 
that play essential roles in the replication process. However, selection of resistance-associated 
variants (RAVs) during DAA therapy has been a major cause of therapeutic failure. In this study 
we wished to address whether such RAVs could be controlled by the co-administration of host-
targeting entry inhibitors that prevent intrahepatic viral spread.  
Design: We investigated the effect of adding an entry inhibitor (the anti-SR-BI mAb1671) to a 
DAA-monotherapy (the protease inhibitor Ciluprevir) in human-liver mice chronically infected 
with HCV of genotype 1b. Clinically relevant non-laboratory strains were used to achieve 
viremia consisting of a cloud of related viral variants (quasispecies) and the emergence of RAVs 
was monitored at high-resolution using next-generation sequencing. 
Results: HCV infected human-liver mice receiving DAA-monotherapy rapidly experienced on-
therapy viral breakthrough. Deep sequencing of the HCV protease domain confirmed the 
manifestation of drug-resistant mutants upon viral rebound. In contrast, none of the mice treated 
with a combination of the DAA and the entry inhibitor experienced on-therapy viral 
breakthrough, despite detection of RAV emergence in some animals.  
Conclusion: This study provides preclinical in vivo evidence showing that addition of an entry 
inhibitor to an anti-HCV DAA regimen restricts the breakthrough of DAA-resistant viruses. Our 
approach is an excellent strategy to prevent therapeutic failure caused by on-therapy rebound of 
DAA-RAVs. Inclusion of an entry inhibitor to the newest DAA combination therapies may 
further increase response rates, especially in difficult-to-treat patient populations. 
 
Summery Box: 
What is known about this subject? 
-DAA monotherapy selects therapy resistant HCV variants leading to therapy failure. 
-RAVs can be detected in patients that fail the newest highly effective DAA combination 
therapies 
-Entry inhibitors have been shown to potently block the spread of HCV in cell culture and in 
small animal models. 
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-In cell culture models, entry inhibitors have additive to synergistic activity to DAAs and 
effectively block the spread of DAA-resistant HCV mutants. 
What are the new findings? 
-Deep sequencing technology revealed rapid emergence of drug-resistant HCV mutants 
coinciding with virus rebound during a DAA therapy in the most relevant small animal model for 
HCV. 
-Humanized mice receiving the DAA monotherapy almost always experienced on-therapy viral 
breakthrough. 
-Addition of an entry inhibitor to this DAA therapy prevented on-therapy rebound of DAA-
RAVs. 
Impact on clinical practice in the foreseeable future: 
RAVs can be detected in difficult-to-treat patients that fail the newest highly potent DAA 
combination therapies. The addition of an entry inhibitor to a DAA cocktail may further increase 
response rates in such patients. In addition, our strategy could be used in a liver transplant setting 
in order to prevent HCV recurrence. Finally this approach could also be utilized in the event of 
global dissemination of therapy-induced DAA resistant viruses.  
In a broader context, an analogous strategy could be implemented for the treatment of other 
viruses that use spread to neighboring host cells as a means to propagate drug resistance. 
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Introduction 
Approximately 3% of the world’s population is chronically infected with the hepatitis C virus 
(HCV), a condition that can lead to liver fibrosis, cirrhosis, and hepatocellular carcinoma and has 
become the leading indication for liver transplantation in developed nations[1].  
The frequent occurrence of severe side effects as well as treatment failures of pegylated 
interferon and ribavirin (PEG-IFN/RBV)-based anti-HCV therapies has driven the development 
of an increasing range of direct-acting antivirals (DAAs). Although the development of DAAs 
offers the perspective of viral cure in a large majority of patients, one challenge for the success 
of DAA therapy has been the emergence of drug resistant mutants[2 3]. While the first 
generation of licensed protease inhibitors (PIs)[4 5] possessed low barriers to resistance in 
combination with PEG-IFN/RBV, improved sustained virologic response (SVR) rates have 
subsequently been achieved with second wave PIs. Nevertheless, despite recent therapeutic 
advances including IFN-free regimens, selection of resistant strains still occurs in difficult-to-
cure patient groups[6], which could become increasingly prevalent in real-life clinical practice 
due to suboptimal therapy adherence. 
The Scavenger Receptor class B type I (SR-BI) is a host factor used by HCV during cell 
entry[7]. SR-BI targeting monoclonal antibodies (mAbs) have been shown to possess cross-
genotypic anti-HCV activity in human-liver mice[8 9] and to inhibit cell-to-cell transmission in 
vitro and intrahepatic spread in vivo[10]. By potently inhibiting the spread of resistant variants 
selected during DAA therapy, anti-SR-BI mAbs may be able to prevent on-therapy breakthrough 
of RAVs and improve overall SVR rates in hard-to-treat patient groups. As a proof-of-concept 
study, we investigated the effect of adding the SR-BI-targeting mAb1671 to PI monotherapy 
(Ciluprevir) in human-liver mice[11 12] chronically infected with HCV gt1b. Chimeric human-
liver mice represent the only small animal model where chronic HCV infection in humans can be 
mimicked[13 14]. A productive viremia consisting of a cloud of related viral variants 
(quasispecies) was achieved with clinically relevant non-laboratory strains and the emergence of 
RAVs monitored at high-resolution using next-generation sequencing. 
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Results  
In vivo virologic response during mono- and combination therapy 
During PI monotherapy, five out of seven mice experienced viral breakthrough (defined by a 
greater than 10-fold increase in HCV RNA over nadir, or when viral RNA becomes quantifiable 
after having been below the LOQ) (Fig. 1a-g). End-of-treatment (EOT) response (HCV RNA 
below LOQ at day 42) was observed in only two mice (Fig. 1f and g). In the combination 
therapy arm, no viral breakthrough was observed, with EOT responses in four out of five mice 
(Fig. 1i-l).  
The mono- and combination therapy arms had similar median viral loads at baseline (P>0.99) 
and comparable reductions in median viremia during the first two weeks of treatment (-
2.17xlog10 and -1.86xlog10, respectively) (Fig. 2). However, the median viremia diverged 
markedly between these treatment groups from day 14 to EOT (day 42) (+2.12xlog10 and -
0.59xlog10, respectively) and also when considering the complete treatment period (-0.05xlog10 
and -2.45xlog10, respectively). In contrast to the monotherapy group (Fig. 2a), the median 
viremia at EOT was significantly reduced in the combination therapy group (P = 0.0079)(Fig. 
2b).  
In order to determine if mAb1671 exerts an antiviral effect in chronic infection, three gt1b 
infected chimeric mice received mAb1671 monotherapy over a four-week period (Fig. 3). HCV 
RNA in the plasma of these mice did not fluctuate more than what is routinely observed in non-
treated infected animals. 
 
Quasispecies analysis during therapy  
The observed differences in EOT outcome were primarily due to the occurrence of on-therapy 
viral rebound in the monotherapy animals. To investigate whether these breakthrough viruses 
represented drug-resistant variants, we tracked the evolution of the protease region of the viral 
genome via Illumina deep sequencing technology. Nucleotide coverage across the protease 
domain was consistent between samples and independent of study phase or treatment regimen 
(see supplemental Fig. 1a). Viral genomic input into sequencing amplicons was determined 
empirically and ranged between 1×10
3
 and 3×10
6
 genomes
 
(see supplemental Fig. 1b), 
representing orders of magnitude greater population sampling than conventional clonal 
sequencing. 
 
As previously described [15], the vast majority of variation in the NS3 protease region was 
detected at silent sites. Besides a minor fraction (< 2.2 %) of D168A mutants in the viral 
population of one mouse (Fig. 1i), PI-RAVs were not detectable at baseline in the remaining 11 
animals (Fig. 1). However, in all mice of the monotherapy cohort that experienced a viral 
breakthrough, PI-RAVs consistently became dominant during viral rebound (Fig. 1a-e). The 
most frequently identified mutation was the D168V substitution, a mutation known to confer 
resistance to Ciluprevir and other PIs[16 17]. The detection of D168V in monotherapy treated 
animals was correlated with viral breakthough in all cases. In some animals, transient low-level 
R155Q and A156V/T RAVs were detectable at nadir, but these became undetectable following 
viral rebound (data not shown). This observation is not surprising since R155Q and A156V/T 
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mutations reduce the replicative capacity of the mutated virus to 10 and18/30% of that of the 
wild type, while the fitness of the D168V mutant remains nearly unaffected[17]. In mice 
achieving EOT response upon PI-monotherapy, exclusively wild type sequences were detected 
(Fig. 1f and g). In the combination therapy cohort, however, treatment response did not correlate 
with the absence of detectable PI-RAVs. Indeed, although no on-therapy viral rebounds were 
observed, two mice presented with RAVs during therapy (Fig. 1h and i) and one developed a 
minor D168G population (3.1%) at EOT (Fig. 1j). Therefore, the occurrence of RAV D168V 
was not correlated with viral breakthrough in the dual therapy arm, indicating the viremia 
remained controlled, independent of PI-RAVs development, as long as the entry inhibitor was 
co-administered.  
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Discussion  
Our results demonstrate that during PI treatment, plasma HCV RNA levels declined in two 
phases: an initial rapid decline followed by a more gradual one. During the first two weeks of 
treatment the mono- and combination therapy arms had a similar reduction in median viremia, 
whereas during a second phase the median viremia diverged markedly between these two 
treatment groups. This suggests that addition of an entry inhibitor is probably not increasing the 
antiviral effect of the DAA during the early phase of therapy. Accordingly, our SR-BI antibody 
did not significantly influence the viremia in chronically infected control animals (Fig. 3). In two 
recent publications it was shown that monotherapy with other entry inhibitors, an antibody 
against claudin-1 and an anti-envelope antibody, had antiviral activity in a setting of chronic 
HCV [18 19]. The cause of this potential discrepancy is currently under investigation but may be 
related to distinct characteristics of the viral strains used or to differences in the mode-of-action 
between these entry inhibitors. 
Nevertheless, mAb1671 appeared to strongly affect the second phase of viral decline, which was 
greater and more sustained in mice that received Ciluprevir in combination with mAb1671 than 
in mice that received Ciluprevir alone. Moreover, during the second phase, the animals from the 
single therapy group experienced a rebound in median viral titer rather than a continued viral 
decline (Fig. 2). Indeed, the median change in plasma RNA levels from day 14 to day 42 was -
0.59-log10 and +2.12-log10 for the combination and single therapy group respectively. This 
difference can be attributed to viral breakthroughs that were solely observed in the PI 
monotherapy group. 
Comparison of the two groups over the complete treatment period clearly indicates the 
superiority of the combination over the monotherapy regimen. Since our entry inhibitor alone has 
no effect on the viral load in chronically infected animals, its observed additional antiviral effect 
must depend on another function. We have previously shown that mAbs against SR-BI can 
efficiently inhibit intrahepatic viral spread [8 9]. Therefore, we hypothesize that this entry 
inhibitor is able to protect cured cells from re-infection and prevent the spread of therapy 
resistant variants, thereby precluding their on-therapy breakthrough. Indeed, during PI 
monotherapy, rapid emergence of PI-resistant variants occurred that resulted in their immediate 
breakthrough (Fig. 1a-e). In clear contrast, viral breakthrough was not observed in any of the 
animals receiving combination therapy (Fig. 1h-l), not even in those in which the D168V 
mutation was detected during therapy (Fig. 1h and i).  
Of note, despite the absence of PI-resistant variants at baseline in all but one mouse, we cannot 
exclude that these were not present at frequencies below the limit of detection of our deep 
sequencing detection method [20]. Besides the selection of pre-existing resistant viruses, 
resistance mutations can rapidly be acquired by wild type virus during therapy[21]. 
Until now, most companies have been developing DAAs that specifically target the non-
structural proteins of HCV. The rationale for this is that such an approach is more targeted 
causing fewer side effects than when host cell proteins are targeted, where the natural function 
could become impaired. Nevertheless, a monoclonal antibody very similar to mAb1671 targeting 
the host cell receptor SR-BI, was shown to be safe in macaques[22]. In addition, evidence for 
clinical safety of SR-BI inhibition is provided by studies involving the SR-BI-specific small 
molecule inhibitor ITX-5061[23 24]. The more conserved nature of host factors compared to the 
viral proteins makes the former interesting potential therapeutic targets. Although also different 
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HCV variants have been described that are less dependent on SR-BI for cell entry in vitro, we 
recently demonstrated that the anti-SR-BI mAb1671 remains fully effective against such viruses 
in vivo, which could be explained by the increased efficacy of the antibody therapy in the 
presence of human lipoproteins[10]. 
It is assumed that entry inhibitors for HCV could be used as a constituent of a drug cocktail 
together with specifically targeted DAAs, comparable to the use of Maraviroc and Enfuvirtide 
for the treatment of HIV-1 infections[25]. Therefore it would be interesting to determine how 
these different drug classes interact or cooperate in the context of HCV infection. HCV entry 
inhibitors have additive to synergistic antiviral activity to DAAs in vitro[26-28] and do not 
develop cross-resistance with DAAs[29]. One small pilot study suggests synergistic activity of 
an SR-BI mAb in combination with a DAA in human-liver mice[26].  
Although mAb1671 is clearly able to prevent on-therapy viral rebound, SVR was not seen in 
either treatment group indicating that a longer treatment regimen is required to achieve viral 
clearance, especially in immune deficient hosts like the SCID mice used here. Considering the 
recent availability of highly potent anti-HCV DAA combinations, it is foreseeable that the 
clinical applicability of entry inhibition in the context of HCV infection may initially be limited 
to specific, difficult-to-treat patient populations. Recent reports highlight that RAVs may still 
have an impact on the outcome of the newest interferon-free DAA combination therapies. Forns 
et al. reported that patients with a history of relapse after PEG-IFN/RBV/PI therapy and that 
harbored NS3 and/or NS5A RAVs at baseline responded less well to Grazoprevir-Elbasvir 
combination therapy compared to patients without these RAVs (66,7-91,2% versus 100%)[30]. 
In addition, new RAVs emerged at the NS3 or NS5A loci in the three patients that experienced 
virologic failure. Lawitz and colleagues reported that the success of a prolonged retreatment of 
patients, who previously failed Ledipasvir/Sofosbuvir-based regimens, with 
Ledipasvir/Sofosbuvir was heavily impacted by the baseline presence of NS5A RAVs (50-69% 
SVR12 in patients with one or more RAVs vs. 100% SVR12 in patients without RAVs)[31]. 
Interestingly, although none of the patients had baseline NS5B RAVs, 33% of patients that 
experienced virologic failure had developed one or two NS5B RAVs (S282T and/or L159F). 
Similarly Poordad et al., showed that about 30% of patients that failed a short-term 
Grazoprevir/Elbasvir/Sofosbuvir treatment had emerging NS5A RAVs at virologic failure[32]. 
NS5A RAVs also emerged in the majority of both advanced cirrhotic and post-transplant patients 
that relapsed after Sofosbuvir/Daclatasvir/RBV therapy[33]. Importantly, in contrast to NS3 
RAVs, NS5A RAVs tend to persist at high frequency and for a long time (>96 weeks) after 
cessation of therapy, hampering subsequent treatment with NS5A-specific inhibitors[34]. 
 
In summary, our study shows that SR-BI blockade via mAb1671 administration limits 
breakthrough of PI-RAVs during PI therapy. These data thus demonstrate the effectiveness of an 
entry inhibitor targeting a host cell receptor, administered in combination with DAAs, at 
controlling HCV viremia in a pre-clinical small animal model. Clinical safety and efficacy 
studies are needed to evaluate whether addition of an entry inhibitor to a cocktail comprised of 
solely DAAs would suffice to reach SVR, without the need of IFN and RBV. 
Our therapeutic approach could also be utilized in the event of global dissemination of therapy-
induced DAA resistant viruses. In a broader context and similar to HIV-1, an analogous strategy 
could be implemented for the treatment of other viruses including hepatitis B virus, measles 
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virus or human T-lymphotropic virus type 1 (HTLV-1), which may also use spread to 
neighboring host cells as a means to propagate drug resistance[25 35]. 
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Materials and Methods 
In vivo HCV treatment 
Human liver-uPA-SCID mice (chimeric mice) were produced as previously described[11 12 36 
37]. All mice were transplanted with primary human hepatocytes obtained from a single donor 
(donor HH223; BD Biosciences, Erembodegem, Belgium). The effect of the protease inhibitor, 
Ciluprevir, was evaluated in 12 human-liver mice that were infected with a clinical HCV isolate 
of gt1b. Virus was inoculated at least four weeks prior to start of therapy. All mice had over 2 
mg/ml of human albumin in their plasma at time of infection. Seven of these mice received 
Ciluprevir monotherapy while five mice were treated with mAb1671 (produced as 
described[38]) in addition to the protease inhibitor. Ciluprevir was administered by oral gavage 
twice daily at 10 mg/kg for a maximum period of six weeks; two mice were treated for only 5 
weeks (Fig. 1d and 1l). In total 14 intraperitoneal (IP) injections of mAb1671 were given (400 
µg per injection) on day 0, 2, 4, 7, 10, 13, 16, 20, 23, 27, 30, 34, 37, 41. One mouse only 
received the first 12 injections (Fig. 1l). Two mice in the monotherapy cohort did not reach the 
end-of treatment (EOT) time point; one was found dead (Fig. 1e, latest available time point: day 
20) and the other was sacrificed (Fig. 1b, latest available time point: day 15) for liver and blood 
collection. In addition, the effect of mAb1671 monotherapy was assessed. Three gt1b infected 
mice received a 4-week mAb1671 therapy consisting of three IP injections per week (400µg per 
injection at day 0, 2, 4, 7, 9, 11, 14, 16, 18, 21, 23 and 25). For most infections, a serum-derived 
virus was used that had been isolated from an HCV-infected liver transplant patient (genotype 
1b; P05[39]). Two mice (Fig. 1j and one mouse in Fig. 3) were infected with another gt1b patient 
isolate. HCV RNA in plasma was quantified using the COBAS Ampliprep/COBAS TaqMan 
HCV test (Roche Diagnostics, Belgium). Due to dilution of the mouse plasma, the limit of 
quantification (LOQ = 100% LOD) equaled 750 IU/ml. The study protocol was approved by the 
Animal Ethics Committee of the Faculty of Medicine and Health Sciences of the Ghent 
University. 
Identification of HCV Ciluprevir-resistant mutations: deep sequencing 
RNA extraction and cDNA synthesis  
Viral RNA was extracted from mouse EDTA-plasma samples using a MiniElute Viral RNA Spin 
Kit (Qiagen) according to the manufacturers instructions. Viral RNA was eluted in 30µL buffer 
AVE and stored at -80°C. Viral RNA (8 µL) was reverse transcribed using the SuperScript III 
First Strand Synthesis System (Invitrogen) according to the manufacturer’s instructions for gene-
specific primer (GSP) cDNA synthesis utilising a subtype 1b-specific primer at 20 µM  (5’ 
GCTTTTGCCGCTGCCRGTGG -3’). The 20µL total cDNA synthesis reaction was incubated at 
50°C for 1 hour followed by 42°C for 1 hour, prior to heat inactivation at 85°C for 5 min. Input 
viral RNA was then digested away from cDNA/RNA hybrids using RNase H for 20 min at 37°C. 
Viral cDNA was stored at -20°C prior to amplicon generation. 
Amplicon generation  
Amplicon generation for Illumina sequencing was achieved via nested PCR and was performed 
as previously described[15], replacing subtype 1a-specific primers pairs with 1b-specific primers 
pairs. Briefly, 1st round amplifications were performed in 50 µl volumes containing  0.2 µM of 
each 1st round primer (sense primer: 5’-GGACATCATYTYGGGYYTRC-3’; antisense primer:  
5’-GCTTTTGCCGCTGCCRGTGG -3’), 1.5 U Platinum Taq High Fidelity polymerase 
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(Invitrogen), 1x High Fidelity polymerase buffer, 2 mM MgSO4 and 5 µl of viral cDNA. 
Cycling parameters comprised initial denaturation at 94°C for 2 minutes followed by ×35 cycles 
of 94°C for 15 seconds, 50°C for 30 seconds and 68°C for 2 minutes, with a final extension step 
at 68°C for 10 minutes. Second round amplifications were performed using identical conditions 
to the 1st round, except 5 µl of 1st round product was used as template and 2nd round primers 
replaced 1st round primers (sense primer: 5’- GGGGTGGAAGCTCCTYGCGCC -3’; antisense 
primer:  5’- ACTTGRAATGTCTGCGGTAC -3’). Cycling parameters for 2nd round 
amplification were identical to the 1st round with minor modifications: cycle number was 
increased to ×45, a touchdown methodology was employed where annealing temperature was 
gradually reduced from 58°C to 48°C over the course of the ×45 cycles and the annealing time 
was reduced from 2 minutes to 1.5 minutes. Amplicons were cleaned-up using QIAquick PCR 
purification columns (Qiagen) and sequenced using BigDye™ v3.1 (Applied Biosystems) prior 
to Illumina sequencing. 
5’ NCR Quantitative PCR  
To determine viral cDNA input into Illumina sequencing amplicons, quantitative realtime PCR 
amplification of viral cDNA was performed using a Stratagene MX3005p instrument in 20 µl 
volumes containing 0.2 µM forward (5’ - GCGCAACCGGTGAGTACA -3’) and reverse (5’ - 
ACTCGCAAGCACCCTATCAG -3’) primers, 1.0 µl viral cDNA and 10 µl of 2X SYBR Green 
JumpStart Taq ReadyMix (Sigma) reagent with additional ROX reference dye as per the 
manufacturer’s instructions. Ten-fold serial dilutions of the HCV molecular clone JFH-1 from 
10
6
 to 10
1
 copies were co-amplified to generate a standard curve for absolute quantification. All 
samples, standards and negative controls were repeated in triplicate. Cycling conditions 
comprised initial denaturation at 95°C for 2 minutes, followed by 50 cycles of 95 °C for 30 
seconds, 60 °C for 30 seconds, 72 °C for 30 seconds, with a further denaturation for 1 minute at 
95 °C followed by a temperature gradient from 55 °C to 95 °C at 30 seconds / °C to determine 
amplicon melt peaks. Data was analysed using MxPro software (Stratagene) to determine 
product quantity and specificity. 
Illumina MiSeq Sequencing and Data Analysis 
Sequencing library preparation was then performed using TruSeq DNA PCR-Free Sample 
Preparation Kit (Illumina Inc., San Diego, CA, USA) according to the manufacturer’s 
instructions. Prior to Illumina MiSeq sequencing, quality control of libraries was performed with 
an Agilent Bioanalyzer HS Chip (Agilent Technologies) and quantification performed using 
qPCR (KAPA Library Quantification Kit). Bidirectional sequencing of fragmented amplicon 
libraries was then performed (300 cycles) using a MiSeq Reagent Kit v3 (Illumina Inc.) 
according to the manufacturer’s protocol. Generated sequence data was analyzed as previously 
described[15], with minor modifications: read quality checking, contig assembly against a 
reference sequence, coverage plotting and population variant calling were performed using CLC 
Genomics Workbench Version 8 (Qiagen).   
Graphs and statistics 
All graphs were prepared with GraphPad Prism v5 (GraphPad Software Inc., La Jolla, CA, 
USA). To analyze whether differences in median viremia were statistically significant, the 
unpaired nonparametric two-tailed Mann-Whitney test was performed using GraphPad InStat 
v3.06 (GraphPad Software Inc.). 
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Figure legends: 
 
Fig. 1. HCV viremia and protease population variant composition at residue 168 prior to, during 
and following Ciluprevir therapy with and without the addition of an entry inhibitor (the 
SR-BI-specific antibody mAb1671) in human-liver mice. Twelve gt1b-infected mice 
were divided over two study groups, each panel represents a single animal. Seven 
received Ciluprevir monotherapy (a-g, shown in red), and five received the combination 
of Ciluprevir with mAb1671 (h-l, shown in green). The shaded area indicates the 
duration of therapy. Each data point represents the plasma HCV RNA level (IU/ml) of an 
individual subject at a given time. The limit of quantification (LOQ) equals 750 IU/ml. 
Illumina deep-sequencing analysis of the HCV protease domain in NS3 was performed at 
indicated time points (black and red arrows indicate successful and unsuccessful 
generation of sequencing amplicons respectively). The amino acid population frequency 
at position 168 is presented as horizontal bars accompanying the graphs. The wild type 
amino acid, Aspartic acid (D), is represented in blue, whereas mutants have been 
assigned other colors.  
 
Fig. 2. Comparison of median viremia between day -1, 14 and 42 in Ciluprevir monotherapy (a) 
and Ciluprevir/mAb1671 combination (b) therapy groups. Day -1 represents baseline 
viremia prior to start of therapy. End-of-therapy (day 42) viremias are available for five 
mice in each group. The Whiskers contain all values. P values compare median viremias 
between baseline and end-of-therapy in one treatment group using the unpaired 
nonparametric two-tailed Mann-Whitney test. 
 
Fig. 3. Evaluation of the antiviral effect of the SR-BI-specific antibody mAb1671 alone in 
humanized mice chronically infected with gt1b. Three gt1b infected mice received 
mAb1671 three times weekly during four weeks. Each data point represents the plasma 
HCV RNA level (IU/ml) of an individual chimeric mouse at a given time point. The limit 
of quantification (LOQ) equals 750 IU/ml.  
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